Answer
In clinical studies of previously untreated patients receiving Biktarvy through 144 weeks, the most frequently reported adverse reactions were headache (5%), diarrhoea (5%) and nausea (4%).
Sources for this answer
- Biktarvy 50 mg/200 mg/25 mg film-coated tabletsGilead Sciences Ltd · emc · SmPC §4.8 Undesirable effects · Version 21Document updated
Sources checked